Third Rock Ventures IV, L.P.

October 14, 2026

Pompe Disease Market Expected to Grow Through 2036. A new market report projects expansion in the Pompe Disease sector from 2026 to 2036, driven by next-generation enzyme replacement therapies and pipeline innovation. This industry growth is relevant to Maze Therapeutics, which operates in this therapeutic area. The report highlights broader market trends rather than company-specific financial results.

October 16, 2026

Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026. Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.

October 8, 2026

DNTH Highlighted by Benzinga and Announces Nasdaq Inducement Grants. Dianthus Therapeutics was named one of the top three health‑care stocks in a recent Benzinga feature that looks at companies that could help improve a portfolio this quarter. The company also disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4), a filing that relates to compliance with Nasdaq’s listing standards. Both items raise the company’s public profile and address regulatory requirements.